DE69631141D1 - Biologisch aktive peptide und ihre zubereitungen und verwendungen - Google Patents

Biologisch aktive peptide und ihre zubereitungen und verwendungen

Info

Publication number
DE69631141D1
DE69631141D1 DE69631141T DE69631141T DE69631141D1 DE 69631141 D1 DE69631141 D1 DE 69631141D1 DE 69631141 T DE69631141 T DE 69631141T DE 69631141 T DE69631141 T DE 69631141T DE 69631141 D1 DE69631141 D1 DE 69631141D1
Authority
DE
Germany
Prior art keywords
preparations
biologically active
active peptides
derivatives
geodiamolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631141T
Other languages
English (en)
Other versions
DE69631141T2 (de
Inventor
Raymond Andersen
John Coleman
Silva Dilip De
Fangming Kong
Edward Piers
Debra Wallace
Michel Roberge
Theresa Allen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE69631141D1 publication Critical patent/DE69631141D1/de
Publication of DE69631141T2 publication Critical patent/DE69631141T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69631141T 1995-04-20 1996-04-22 Biologisch aktive peptide und ihre zubereitungen und verwendungen Expired - Lifetime DE69631141T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9508195 1995-04-20
GBGB9508195.6A GB9508195D0 (en) 1995-04-20 1995-04-20 Novel biologically active compounds and compositions,their use and derivation
PCT/GB1996/000942 WO1996033211A1 (en) 1995-04-20 1996-04-22 Biologically active peptides and compositions, their use

Publications (2)

Publication Number Publication Date
DE69631141D1 true DE69631141D1 (de) 2004-01-29
DE69631141T2 DE69631141T2 (de) 2004-09-30

Family

ID=10773352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631141T Expired - Lifetime DE69631141T2 (de) 1995-04-20 1996-04-22 Biologisch aktive peptide und ihre zubereitungen und verwendungen

Country Status (12)

Country Link
US (4) US6153590A (de)
EP (1) EP0839154B1 (de)
JP (2) JP4008493B2 (de)
AT (1) ATE256698T1 (de)
AU (1) AU5341696A (de)
CA (1) CA2220021C (de)
DE (1) DE69631141T2 (de)
DK (1) DK0839154T3 (de)
ES (1) ES2213173T3 (de)
GB (1) GB9508195D0 (de)
PT (1) PT839154E (de)
WO (1) WO1996033211A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225325A1 (en) * 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
NZ525730A (en) * 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
PL219737B1 (pl) * 2002-03-22 2015-07-31 Eisai R & D Man Co Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny
CN1705639A (zh) * 2002-09-20 2005-12-07 惠氏控股公司 用于合成微管蛋白抑制剂的中间体的合成方法
WO2004026293A2 (en) * 2002-09-20 2004-04-01 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
JP4549862B2 (ja) * 2002-10-30 2010-09-22 メルク・シャープ・エンド・ドーム・コーポレイション クロマトグラフィーにおける移動相改質剤としてのアミンまたはアミノ酸の使用
WO2004047615A2 (en) * 2002-11-21 2004-06-10 Wyeth Hemiasterlin affinity probes and their uses
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7390910B2 (en) * 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1768671A2 (de) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Verwendung von ecteinascidin bei der behandlung von krebs bei patienten mit niedrigen brca1-konzentrationen
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
PL1658848T3 (pl) * 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
CA2607257A1 (en) * 2005-05-05 2006-11-16 Eisai Co., Ltd. Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2118127A4 (de) * 2007-01-31 2010-12-01 Affymax Inc Linker auf stickstoffbasis zur bindung modifizierender gruppen an polypeptide und andere makromoleküle
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
EP2448585B1 (de) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinon-substituiertes azepin[b]indol und pyrido-pyrrolo-azepin mch-1 antagonisten, verfahren zur herstellung und verwendung davon
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
CN103570603A (zh) * 2012-07-19 2014-02-12 杭州中肽生化有限公司 哈米特林的一种合成新方法
JP6431038B2 (ja) 2013-03-15 2018-11-28 ザイムワークス インコーポレイティド 細胞毒性及び抗有糸分裂性化合物とその使用方法
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
KR20160125361A (ko) 2013-12-27 2016-10-31 자임워크스 인코포레이티드 Ｖａｒ２ｃｓａ－약물 접합체
HUE057768T2 (hu) 2014-09-17 2022-06-28 Zymeworks Inc Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei
JP7011830B2 (ja) 2015-10-14 2022-01-27 エックス－サーマ インコーポレイテッド 氷晶形成を低減するための組成物および方法
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CN111032676A (zh) * 2017-08-10 2020-04-17 大日本住友制药株式会社 包含哈米特林衍生物的抗体药物复合物
WO2019031615A1 (ja) * 2017-08-10 2019-02-14 大日本住友製薬株式会社 ヘミアスタリン誘導体及びこれらの抗体薬物複合体
WO2020166613A1 (ja) * 2019-02-13 2020-08-20 大日本住友製薬株式会社 多能性幹細胞の除去剤
US20220144889A1 (en) * 2019-02-13 2022-05-12 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin Derivative Having Cysteine Residue

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2904512A1 (de) * 1979-02-07 1980-08-28 Troponwerke Gmbh & Co Kg Dehydropeptide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
NZ194747A (en) * 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4820691A (en) 1987-06-24 1989-04-11 E. R. Squibb & Sons, Inc. Amino acid 1,2-diketo derivatives as renin inhibitors
US5081225A (en) * 1989-02-09 1992-01-14 E. R. Squibb & Sons, Inc. Gram-positive and gram-negative antibacterial compounds from the microorganism, janthinobacterium lividum
US5340802A (en) * 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
CA2042027A1 (en) * 1989-09-15 1991-03-16 Arthur E. Bogden Treatment of colon cancer
FR2681075B1 (fr) * 1991-09-05 1994-09-16 Commissariat Energie Atomique Preparation enzymatique purifiee issue de chromobacterium violaceum, son procede d'obtention et son application a la production d'alpha,beta-dehydrotryptophanyl-peptides.
WO1993017701A1 (en) * 1992-03-12 1993-09-16 The Administrators Of The Tulane Educational Fund Endothelin receptor-binding peptides
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5661175A (en) * 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof

Also Published As

Publication number Publication date
WO1996033211A1 (en) 1996-10-24
US20090088573A1 (en) 2009-04-02
DK0839154T3 (da) 2004-04-19
JP2007031441A (ja) 2007-02-08
EP0839154B1 (de) 2003-12-17
ATE256698T1 (de) 2004-01-15
US20050171137A1 (en) 2005-08-04
US7772397B2 (en) 2010-08-10
US7410951B2 (en) 2008-08-12
ES2213173T3 (es) 2004-08-16
DE69631141T2 (de) 2004-09-30
GB9508195D0 (en) 1995-06-07
PT839154E (pt) 2004-05-31
US6153590A (en) 2000-11-28
JPH11505211A (ja) 1999-05-18
CA2220021A1 (en) 1996-10-24
AU5341696A (en) 1996-11-07
JP4006466B2 (ja) 2007-11-14
JP4008493B2 (ja) 2007-11-14
EP0839154A1 (de) 1998-05-06
US6870028B1 (en) 2005-03-22
CA2220021C (en) 2012-06-26

Similar Documents

Publication Publication Date Title
ATE256698T1 (de) Biologisch aktive peptide und ihre zubereitungen und verwendungen
NL350077I1 (nl) Cyprosulfamide
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
PT765152E (pt) Estimulacao do crescimento capilar por complexos de peptido-cobre
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
AU2291097A (en) Novel phenanthridines substituted in the 6 position
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
TR199800623T2 (xx) Yeni amino asit t�revleri, m�stahzarlar� ve kullan�mlar�.
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
AR021695A1 (es) 4,5-pirazinoxindoles, composicion farmaceutica y uso
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
DE69825626D1 (de) Heterozyklische cytotoxische wirkstoffe
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
SE0003476D0 (sv) Compounds
DE69612056T2 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE414100T1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition